Drug Profile


Alternative Names: Beleodaq; CLN-9; ComboBelCHOP; PDX 101; PX-105684; PXD 101

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator TopoTarget
  • Developer CIMA- Universidad de Navarra; Emory University; National Cancer Institute (USA); Onxeo SA; Spectrum Pharmaceuticals; TopoTarget
  • Class Acrylamides; Antineoplastics; Hydroxamic acids; Small molecules; Sulfonamides
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Peripheral T-cell lymphoma; Thymoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Peripheral T-cell lymphoma
  • Phase II B cell lymphoma; Glioblastoma
  • Phase I/II Non-small cell lung cancer
  • Phase I Acute myeloid leukaemia; Lymphoma; Myelodysplastic syndromes; Small cell lung cancer; Solid tumours
  • Preclinical Hepatocellular carcinoma
  • No development reported Bladder cancer; Carcinoma; Colorectal cancer; Cutaneous T cell lymphoma; Fallopian tube cancer; Mesothelioma; Ovarian cancer; Peritoneal cancer; Soft tissue sarcoma; Thymoma
  • Discontinued Multiple myeloma

Most Recent Events

  • 24 Apr 2017 Onexo in collaboration with Clinigen's Idis Managed Access division initiates a Managed Access Programme for belinostat for Peripheral T cell lymphoma (Second-line therapy or greater) in Europe
  • 21 Mar 2017 Pharmacodynamics data from a preclinical trial in Hepatocellular carcinoma released by Onxeo
  • 14 Nov 2016 The National Cancer Institute terminates a phase-I/II clinical trial in Thymoma (first-line therapy, combination therapy) in USA (IV) (NCT01100944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top